Sign in

    Joohwan Kim • Canaccord Genuity

    Joohwan Kim is an Associate at Canaccord Genuity, specializing in genetic medicine and rare diseases, and actively collaborates with senior analyst Whitney Ijem. He covers companies such as Rhythm Pharmaceuticals and Generation Bio, participating in major industry events like the Canaccord Genuity Growth Conference where he facilitates discussions with executive leadership from these firms. Kim began his career following completion of his undergraduate degree at Northeastern University and joined Canaccord Genuity as an associate in 2022. His professional credentials reflect a solid foundation in life sciences investment research, with current registration at Canaccord Genuity LLC as listed on major finance directories.

    Joohwan Kim's questions to Arcturus Therapeutics Holdings Inc (ARCT) leadership

    Joohwan Kim's questions to Arcturus Therapeutics Holdings Inc (ARCT) leadership • Q4 2024

    Question

    Joohwan Kim, on for Whitney Ijem, asked for clarity on the magnitude of development costs CSL needs to recoup before Arcturus receives profit-sharing payments and inquired about the next steps for KOSTAIVE's commercialization in the EU.

    Answer

    CFO Andrew Sassine explained that while a specific total for recoupable costs hasn't been disclosed, the recently recognized $28 million share of gross profit contributes toward that amount. He deferred to their partner CSL for details on the EU commercialization strategy but reiterated that Arcturus's cash runway guidance to Q1 2027 does not depend on future KOSTAIVE revenue.

    Ask Fintool Equity Research AI